Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
Medshine Discovery Inc. is managing 6 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 5 distinct examiners and 3 distinct art units. The use of 3 art units for 6 actions indicates that the company's biotech filings are grouped into a few specific technical categories within the patent office, allowing for some administrative consistency. However, the involvement of 5 distinct examiners means that most actions are being reviewed by different individuals.
LEESER, ERICH A is the busiest examiner for the company, overseeing 2 pending office actions. This accounts for a portion of the 6 total pending actions currently active. The remaining actions are split among other distinct examiners, making Leeser the only examiner in the portfolio handling more than a single matter. With 5 distinct examiners in total, the prosecution of these actions is relatively decentralized at the examiner level.
The 3 distinct art units involved suggest that the 5 examiners are concentrated within a limited number of supervisory groups. While LEESER, ERICH A handles 2 pending actions, the other matters are distributed among the remaining examiners. This structure requires the company to manage several different examiner relationships while navigating the norms of the 3 art units in the Biotechnology & Pharmaceuticals space.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| §103 only | 1 (25%) |
| §112 only | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KOSAR, ANDREW D | 1 | 42.0% | +31.8% |
| LEE, WILLIAM Y | 1 | 47.9% | +34.1% |
| LEESER, ERICH A | 1 | 81.8% | +13.3% |
| FETTEROLF, BRANDON J | 1 | 52.0% | +17.4% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18682091 | DEUTERATED NUCLEOSIDE COMPOUNDS AND USE THEREOF | LEESER, ERICH A | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18730769 | CRYSTAL FORM OF ALLYL-CONTAINING METHYLPYRIDOPYRIMIDINE COMPOUND | KOSAR, ANDREW D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18550468 | 6-CARBAMATE SUBSTITUTED HETEROARYL RING DERIVATIVES | FETTEROLF, BRANDON J | 16d overdue |
| 18730769 | CRYSTAL FORM OF ALLYL-CONTAINING METHYLPYRIDOPYRIMIDINE COMPOUND | KOSAR, ANDREW D | — |
| 18703171 | PYRROLOPYRAZOLE SPIRO COMPOUND | LEE, WILLIAM Y | — |
| 18682091 | DEUTERATED NUCLEOSIDE COMPOUNDS AND USE THEREOF | LEESER, ERICH A | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18730769 | CRYSTAL FORM OF ALLYL-CONTAINING METHYLPYRIDOPYRIMIDINE COMPOUND | KOSAR, ANDREW D | — | §101§102§112 | Non-Final OA | — | Pending | Jul 20, 2024 |
| 18703171 | PYRROLOPYRAZOLE SPIRO COMPOUND | LEE, WILLIAM Y | — | §112 | Non-Final OA | — | Pending | Apr 19, 2024 |
| 18682091 | DEUTERATED NUCLEOSIDE COMPOUNDS AND USE THEREOF | LEESER, ERICH A | 1622 | §103 | Non-Final OA | — | Pending | Feb 07, 2024 |
| 18550468 | 6-CARBAMATE SUBSTITUTED HETEROARYL RING DERIVATIVES | FETTEROLF, BRANDON J | 1626 | §112 | Non-Final OA | 16d overdue | Pending | Sep 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial